- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.11.2025 | 1.072 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.11.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.11.2025.ISIN NameCA74971G4016 RF... ► Artikel lesen | |
| 03.11.25 | XFRA 7PL0: AUSSETZUNG/SUSPENSION | 191 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPROSTALUND AB 7PL0... ► Artikel lesen | |
| 24.10.25 | ProstaLund AB: PROSTALUND AB (publ) - Interim report January-September 2025 | 165 | GlobeNewswire (Europe) | Third quarterJuly 1 - September 30Net sales reached MSEK 2.2 (3.5)Operating profit/loss totaled MSEK -2.6 (-4.4)Loss after taxes MSEK -2.6 (-4.5)Earnings per share, before and after dilution amounted... ► Artikel lesen | |
| 15.10.25 | Delisting of ProstaLund AB from Nasdaq First North Growth Market | 270 | GlobeNewswire | ProstaLund AB has applied for its shares to be delisted from Nasdaq First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the shares of ProstaLund... ► Artikel lesen | |
| 12.09.25 | ProstaLund AB: ProstaLund enters collaboration agreement with the XEN Group for the market in the United Arab Emirates and Oman | 245 | GlobeNewswire (Europe) | ProstaLund has signed a collaboration agreement with the XEN Group, a prominent distributor of advanced innovative products with solid experience and contacts in the UAE and Oman. Through this partnership... ► Artikel lesen | |
| 10.09.25 | ProstaLund AB: ProstaLund enters collaboration agreement with Mayumana Healthcare for the Benelux market | 185 | GlobeNewswire (Europe) | ProstaLund has entered into a collaboration agreement with Mayumana Healthcare, a leading distributor of innovative urological solutions with strong expertise in the Benelux market. The partnership... ► Artikel lesen | |
| 21.08.25 | ProstaLund AB: ProstaLund AB - Interim Report January-June 2025 | 160 | GlobeNewswire (Europe) | April 1 - June 30Net sales reached MSEK 2.1 (2.8)Operating profit/loss totaled MSEK -6.3 (-7.2)Loss after taxes MSEK -6.5 (-7.1)Earnings per share, before and after dilution amounted to SEK -1.80 (-3.72)Cash... ► Artikel lesen | |
| PROSTALUND Aktie jetzt für 0€ handeln | |||||
| 11.07.25 | The observation status for ProstaLund AB is updated | 295 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
Today... ► Artikel lesen | |
| 01.07.25 | The observation status for ProstaLund AB is updated | 243 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
On May... ► Artikel lesen | |
| 30.05.25 | ProstaLund AB: ProstaLund AB - Interim report January-March 2025 | 229 | GlobeNewswire (Europe) | Januari 1 - March 31Net sales reached SEK 3,7 million (3,5)Operating result amounted to -5,0 MSEK (-4,7)Profit after tax amounted to -5,0 MSEK (-4,8)Earnings per share before and after dilution amounted... ► Artikel lesen | |
| 23.05.25 | XFRA 7PL0: WIEDERAUFNAHME/RESUMPTION | 441 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 23.05.25 | The observation status for ProstaLund AB is updated | 312 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
On May... ► Artikel lesen | |
| 21.05.25 | Lift of Suspension in ProstaLund AB at FNSE | 332 | GlobeNewswire | 2025-05-21T15:00:36Z
Lifting of Suspension
At Trading Venue FNSE
Ended on:
2025-05-21T14:50:00Z
Ongoing: False
Comments: Nasdaq Stockholm has, to the
extent applicable, also decided to lift the suspension... ► Artikel lesen | |
| 20.05.25 | ProstaLund AB: First patients treated with CoreTherm Eagle | 316 | GlobeNewswire (Europe) | The first patients with benign prostatic hyperplasia have been successfully treated using our new CoreTherm® Eagle platform.
"We are very pleased that the first patients have been successfully treated... ► Artikel lesen | |
| 19.05.25 | XFRA 7PL0: AUSSETZUNG/SUSPENSION | 235 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPROSTALUND AB 7PL0... ► Artikel lesen | |
| 19.05.25 | Suspension of Trading in ProstaLund AB at FNSE | 298 | GlobeNewswire | 2025-05-19T07:01:39Z
Suspension
At Trading Venue FNSE
Due to Other
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent applicable, also decided to
suspend the trading in all other instruments... ► Artikel lesen | |
| 20.02.25 | ProstaLund AB: ProstaLund AB - Year-end report 2024 | 219 | GlobeNewswire (Europe) | "With several ongoing contract discussions for CoreTherm® Eagle, we are positive about the interest in our treatment and the upcoming international launch"
Fourth quarterOctober 1 - December 31Net sales... ► Artikel lesen | |
| 14.02.25 | ProstaLund AB: New study confirms the strong efficacy of CoreTherm in patients with large prostates | 308 | GlobeNewswire (Europe) | A newly published Danish study has evaluated the efficacy and safety of CoreTherm® in men with prostate sizes exceeding 100 grams. The median prostate size among participants was 126 g (range: 101-230... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | DAX-Konzern Siemens Healthineers legt Zahlen vor | Siemens Healthineers startet solide ins neue Geschäftsjahr und bestätigt den Jahresausblick, wird aber vom schwachen Diagnostikgeschäft in China gebremst. Der DAX-Konzern Siemens Healthineers ist mit... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | ANALYSE-FLASH: Barclays senkt Carl Zeiss Meditec auf 'Equal Weight' | LONDON (dpa-AFX Broker) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | BREAKING: Hims & Hers verschärft Preisdruck bei Novo Nordisk - Aktie beschleunigt Talfahrt | Der dänische Biopharma-Riese ist erst seit wenigen Wochen mit seinem Appetitzügler Wegovy als Tablette auf dem US-Markt und sieht sich einem massiven Preisdruck ausgesetzt. Das Telehealth-Unternehmen... ► Artikel lesen | |
| UNITEDHEALTH | 232,15 | -0,77 % | UnitedHealth: Das sieht gar nicht gut aus | Der enttäuschende Ausblick, den UnitedHealth dem Kapitalmarkt vor Kurzem an die Hand gegeben hat, und maue Aussichten für 2027 hinterlassen weitere Spuren im Aktienkurs des größten US-Krankenversicherers.... ► Artikel lesen | |
| RXSIGHT | 8,390 | +7,29 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen |
PROSTALUND AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,001 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROSTALUND AB finden Sie auf Wallstreet Online.